{"id":"spn-810-36-mg","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Somnolence"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Weight gain"},{"rate":"5-10%","effect":"Increased appetite"},{"rate":"1-5%","effect":"Rash"},{"rate":"1-5%","effect":"Diarrhea"},{"rate":"1-5%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL5925448","moleculeType":null,"molecularWeight":"421.46"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action of SPN-810 is not fully understood, but it is believed to work by stabilizing mood and reducing the risk of suicidal behavior. SPN-810 is a formulation of divalproex sodium, which is a mood stabilizer that has been used to treat various conditions, including bipolar disorder and epilepsy.","oneSentence":"SPN-810 is a proprietary formulation of a divalproex sodium extended-release product designed to treat disruptive mood dysregulation disorder (DMDD).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:21.352Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Disruptive mood dysregulation disorder (DMDD)"}]},"trialDetails":[{"nctId":"NCT03638466","phase":"PHASE2","title":"Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD","status":"TERMINATED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2019-05-30","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression","enrollment":7},{"nctId":"NCT02691182","phase":"PHASE3","title":"Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)","status":"TERMINATED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2016-04","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":491},{"nctId":"NCT02618434","phase":"PHASE3","title":"Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2016-02-16","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":297},{"nctId":"NCT02618408","phase":"PHASE3","title":"Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2016-01-25","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":333}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SPN-810 (36 mg)","genericName":"SPN-810 (36 mg)","companyName":"Supernus Pharmaceuticals, Inc.","companyId":"supernus-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SPN-810 is an experimental medication being studied for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Impulsive Aggression. It is administered in doses of 18 mg and 36 mg, in addition to a placebo, as part of clinical trials to assess its efficacy and safety.","enrichmentLevel":3,"visitCount":4,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}